Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events

Overview of attention for article published in New England Journal of Medicine, March 2015

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (92nd percentile)

Mentioned by

news: 26 news outlets
blogs: 8 blogs
policy: 3 policy sources
twitter: 63 X users
patent: 10 patents
facebook: 10 Facebook pages

wikipedia: 1 Wikipedia page
googleplus: 1 Google+ user
reddit: 5 Redditors
f1000: 1 research highlight platform
guideline: 17 clinical guideline sources

Readers on

mendeley: 973 Mendeley

So far, Altmetric has seen 11 public wall posts from 10 users.

Primal Docs, 06 Sep 2015

Short term studies funded by big pharma show only a small 1% absolute risk reduction in CV events compared to standard therapy…

Primal Docs, 06 Sep 2015

Short term studies funded by big pharma show only a small 1% absolute risk reduction in CV events compared to standard therapy…

Denver's Diet Doctor, 02 Sep 2015

Will the new blockbuster cholesterol lowering drugs (#PCSK9 inhibitors) burst the US healthcare bubble? Short term studies…

CardioAcademic, 31 Aug 2015

#doc #ESCcongress ORIGINAL…

This page shows the most recent Facebook posts that mention this research output. Click here to find out how to access more activity, including 7 additional Facebook posts.